New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Elephant Talk Communications Corp (NYSEMKT:ETAK), Sonus Networks, Inc (NASDAQ:SONS), Zogenix, Inc (NASDAQ:ZGNX), Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI)
Elephant Talk Communications Corp (NYSEMKT:ETAK) showed a volume of 1.38 million shares by the end of last trade whereas the average volume of the stock remained 779,751.00 shares. The stock opened the session at $1.35 but then moved to $1.49. At that price, the stock showed a positive performance of 7.97%. Elephant Talk Communications Corp. is a provider of mobile networking software and services. The Company provides operating software, managed services, cloud and Software as a Service (SaaS) solutions, an integrated transaction and delivery platform to the mobile telecommunications industry globally. The Company’s products include remote health care, credit card fraud prevention, mobile Internet ID security, secure remote file access management, loyalty and transaction management services and a whole range of other emerging mobile services.
Will ETAK Continue To Move Higher? Find Out Here
Sonus Networks, Inc (NASDAQ:SONS) opened the session at $3.04 and closed the session at $2.94. The stock showed a negative performance of -2.65% in previous trading session. Traded with volume of 1.38 million shares in the prior session and the average volume of the stock remained 1.32 million shares. Sonus Networks, Inc. (Sonus) is a provider of networked solutions for communications service providers e.g., telecommunications, wireless and cable service providers and enterprises to help them advance, protect and unify their communications and improve collaboration. Its products include session border controllers, Session Initiation Protocol (SIP) session management servers, Voice over IP (VoIP) switches, SIP application servers, multiprotocol signaling gateways and network analytics tools.
Has SONS Found The Bottom And Ready To Gain Momentum? Find Out Here
Zogenix, Inc (NASDAQ:ZGNX) opened the session at $3.32 and closed the session at $3.33. The stock showed a positive performance of 0.60% in previous trading session. Traded with volume of 1.37 million shares in the prior session and the average volume of the stock remained 1.92 million shares. The beta of the stock remained 2.54. Zogenix, Inc. (Zogenix) is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The Company’s product Sumavel DosePro offers needle-free subcutaneous administration of sumatriptan for the treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, Zohydro (hydrocodone bitartrate, formerly ZX002) is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of chronic pain requiring opioid therapy.
Why Should Investors Buy ZGNX After The Recent Gain? Just Go Here and Find Out
Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) the stock advanced 1.20% and finished the session at $8.44. Traded with volume of 1.36 million shares in the prior session and the average volume of the stock remained 1.05 million shares. The beta of the stock remained 1.83. Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States, it has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of drug candidates.Apaziquone is studied in two Phase III clinical trials for non-muscle invasive bladder cancer,
Will SPPI Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)